A decade af­ter it first failed, a Shire-de­vel­oped Take­da an­tivi­ral ap­pears suc­cess­ful in Phase III

Near­ly 20 years af­ter it first en­tered the clin­ic and over a decade af­ter it first flunked a Phase III tri­al, a Take­da-owned drug to treat CMV in­fec­tions has proven ef­fec­tive in a late-stage study.

Take­da didn’t break down all the num­bers, but said that in a 352-per­son tri­al, marib­avir out­per­formed physi­cian’s choice in clear­ing in­fec­tions in trans­plant pa­tients who were re­sis­tant to cur­rent treat­ments. In a state­ment, Obi Umeh, Take­da’s marib­avir pro­gram leader, said they would take the da­ta to reg­u­la­tors in the US and Eu­rope.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.